Company news
Sinotherapeutics, Inc. Class A (SSE:688247) news
Sinotherapeutics, Inc. Class A news releases on 6ix. Latest, May 21, 2025: Announcement on the Change of Investor Hotline
Press releases — page 2
Announcement on the Change of Investor Hotline
May 20, 2025
Announcement on Voluntary Disclosure of Obtaining US FDA Approval Number for the Company's Dapagliflozin and Metformin Hydrochloride Sustained-release Tablets
May 12, 2025
Announcement on Changes in Some Directors, Senior Management Members, Financial Chief and Core Technical Personnel
May 5, 2025
Announcement on Canceling the Board of Supervisors and Amending the Articles of Association and Some Management Systems
April 29, 2025
Announcement on Pledge Release of Some Shares Held by Shareholders with Over 5% Shares
March 24, 2025
Announcement on Expiration of Plan of Shareholding Reduction by Shareholder with Over 5% Shares and Results of Shareholding Reduction
March 18, 2025
Indicative Announcement on Equity Change of Shareholders with Over 5% Shares Reaching 1%
March 14, 2025
Announcement on Preliminary Earnings Estimate for 2024
February 26, 2025
Announcement on the Estimated Routine Related Party Transactions for 2025
February 19, 2025
Announcement on Implementation Results of Shares Repurchase
February 18, 2025
Announcement on Progress in Repurchasing Shares
February 5, 2025
Annual Earnings Preannouncement for 2024
January 22, 2025
Announcement on Voluntary Disclosure of the Results of the Company's Products Participating in Centralized Volume-based Procurement of Drugs Organized by the State
December 13, 2024
Announcement on Plan of Shareholding Reduction by Shareholders with over 5% Shares
November 27, 2024
Announcement on Convening the Q3 2024 Performance Briefing
November 25, 2024